Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.

@article{Acker2008DiscoveryON,
  title={Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.},
  author={Brad A. Acker and E. J. Jacobsen and Bruce N. Rogers and Donn G. Wishka and Steven C Reitz and David W Piotrowski and Jason K Myers and Mark L. Wolfe and Vincent E. Groppi and Bruce A Thornburgh and Paula M Tinholt and R. E. Walters and Barbara A Olson and Laura Fitzgerald and Brian A Staton and Thomas J. Raub and Michael Krause and Kai Sum Li and William E. Hoffmann and Mih{\'a}ly Haj{\'o}s and Raymond S. Hurst and Daniel P Walker},
  journal={Bioorganic & medicinal chemistry letters},
  year={2008},
  volume={18 12},
  pages={3611-5}
}
A novel alpha7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective alpha7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model. 
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…